



## Exelixis to Release Second Quarter 2015 Financial Results on Tuesday, August 11, 2015

July 28, 2015

- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 28, 2015-- Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company's website.

To access the webcast link, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the Event Calendar page under Investors & Media. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 94776699 to join by phone.

A telephone replay will be available until 11:59 p.m. EDT on August 13, 2015. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 94776699. A webcast replay will also be archived on [www.exelixis.com](http://www.exelixis.com) for one year.

### About Exelixis

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

*Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.*



View source version on businesswire.com: <http://www.businesswire.com/news/home/20150728006806/en/>

Source: Exelixis, Inc.

*Exelixis, Inc.*

*Susan Hubbard, 650-837-8194*

*Investor Relations and Corporate Communications*

[shubbard@exelixis.com](mailto:shubbard@exelixis.com)